297 related articles for article (PubMed ID: 15603249)
1. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
Brixner DI
Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
[No Abstract] [Full Text] [Related]
2. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
3. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections.
Benninger M; Segreti J
J Fam Pract; 2008 Feb; 57(2 Suppl Managing):S5-11. PubMed ID: 18662527
[No Abstract] [Full Text] [Related]
4. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
Pell DM
Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
[No Abstract] [Full Text] [Related]
5. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
Sbarbaro JA
Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
[No Abstract] [Full Text] [Related]
6. [Systemic antibiotherapy for the treatment of lower respiratory tract infections. Community acquired pneumonia, acute exacerbation of obstructive chronic bronchitis].
Chidiac C; ;
Med Mal Infect; 2011 May; 41(5):221-8. PubMed ID: 21106313
[No Abstract] [Full Text] [Related]
7. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
8. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
9. Barriers to the effective management of respiratory tract infections in the community.
Saginur R
Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
[TBL] [Abstract][Full Text] [Related]
10. Community-acquired pneumonia: treatment at home or in the hospital?
Aujesky D; Fine MJ
Am J Med; 2008 Dec; 121(12):1038-40. PubMed ID: 19028194
[No Abstract] [Full Text] [Related]
11. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
12. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
Starodubtseva OI; Vakhrushev IaM
Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
14. [Guidelines for the epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults].
Höffken G; Lorenz J; Kern W; Welte T; Bauer T; Dalhoff K; Dietrich E; Ewig S; Gastmeier P; Grabein B; Halle E; Kolditz M; Marre R; Sitter H
Dtsch Med Wochenschr; 2010 Feb; 135(8):359-65. PubMed ID: 20166002
[No Abstract] [Full Text] [Related]
15. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
Rakov AL; Grinevich VB; Kriukov AE; Bogdanov IV; Rysev AV; Zakharchenko MM; Dobrenko VA; Gubonina IV
Voen Med Zh; 2006 Apr; 327(4):15-22. PubMed ID: 16784101
[No Abstract] [Full Text] [Related]
17. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Sollet JP
Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
[TBL] [Abstract][Full Text] [Related]
18. [The clinical and economic aspects of treating community-acquired pneumonias].
Tiurin VP; Dmitriev IuK; Duganov VK; Bogdanov MB
Voen Med Zh; 2000 Apr; 321(4):28-31. PubMed ID: 10860468
[No Abstract] [Full Text] [Related]
19. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
